TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
Brief Summary: The goal of this study is to gather input from patients who have undergone PCI, their family and/or caregivers, and clinicians to develop a patient decision aid. The purpose of the decision aid is to deliver information, including individualized estimates of patients' restenosis risk, in an understandable format that would be informative and assist in decision-making for patients undergoing PCI.


Options:
A: Arm Label: Decision aid plus YourDiseaseRisk; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid plus personalized risk assessment | Arm Label: Decision aid alone; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid alone | Arm Label: III; Type: SHAM_COMPARATOR; Interventions: Behavioral: Generic website | Intervention Type: BEHAVIORAL; Name: Web-based decision aid plus personalized risk assessment; Assigned to Arm(s): Decision aid plus YourDiseaseRisk | Intervention Type: BEHAVIORAL; Name: Web-based decision aid alone; Assigned to Arm(s): Decision aid alone | Intervention Type: BEHAVIORAL; Name: Generic website; Assigned to Arm(s): III
B: Arm Label: Heart disease; Type: N/A; Interventions: N/A | Arm Label: Healthy adults; Type: N/A; Interventions: N/A
C: Arm Label: Telephone genetic counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Genetic Counseling | Arm Label: In-person genetic counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In-Person Genetic Counseling | Intervention Type: BEHAVIORAL; Name: Telephone Genetic Counseling; Assigned to Arm(s): Telephone genetic counseling | Intervention Type: BEHAVIORAL; Name: In-Person Genetic Counseling; Assigned to Arm(s): In-person genetic counseling
D: Arm Label: Active Implementation phase; Type: OTHER; Interventions: Other: Uterine Fibroid Option Grid encounter patient decision aid (text only), Other: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Other: Uterine Fibroid Option Grid encounter patient decision aid (online) | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text only); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (online); Assigned to Arm(s): Active Implementation phase

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Randomized Clinical Trial of Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins
Brief Summary: Endovenous laser ablation is a common therapy of great saphenous vein insufficiency with a very high success rate. It works by heating and thereby obliterating the vein. Steam ablation is a new therapy that also works by heating and thereby obliterating the vein. The hypothesis of this study is that steam ablation is as effective as laser ablation, but that it results in better secondary outcomes (e.g., lower pain scores).


Options:
A: Arm Label: Endovenous laser ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovenous laser ablation with 940 nm bare fiber | Arm Label: Endovenous steam ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovenous steam ablation with steam vein sclerosis system. | Intervention Type: PROCEDURE; Name: Endovenous laser ablation with 940 nm bare fiber; Assigned to Arm(s): Endovenous laser ablation | Intervention Type: PROCEDURE; Name: Endovenous steam ablation with steam vein sclerosis system.; Assigned to Arm(s): Endovenous steam ablation
B: Arm Label: EndoVenous Laser Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: EVLA, Drug: Lidocaine with 1:200,000 epinephrine solution, Drug: Sodium Bicarbonate | Arm Label: MechanoChemical Ablation (ClariVein®); Type: ACTIVE_COMPARATOR; Interventions: Device: ClariVein®, Drug: Lidocaine with 1:200,000 epinephrine solution, Drug: Sodium Tetradecyl Sulphate | Intervention Type: DEVICE; Name: EVLA; Assigned to Arm(s): EndoVenous Laser Ablation | Intervention Type: DEVICE; Name: ClariVein®; Assigned to Arm(s): MechanoChemical Ablation (ClariVein®) | Intervention Type: DRUG; Name: Lidocaine with 1:200,000 epinephrine solution; Assigned to Arm(s): EndoVenous Laser Ablation, MechanoChemical Ablation (ClariVein®) | Intervention Type: DRUG; Name: Lidocaine with 1:200,000 epinephrine solution; Assigned to Arm(s): EndoVenous Laser Ablation | Intervention Type: DRUG; Name: Sodium Bicarbonate; Assigned to Arm(s): EndoVenous Laser Ablation | Intervention Type: DRUG; Name: Sodium Tetradecyl Sulphate; Assigned to Arm(s): MechanoChemical Ablation (ClariVein®)
C: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery - Saphenofemoral ligation, saphenous strip and avulsions | Arm Label: EVLT; Type: EXPERIMENTAL; Interventions: Procedure: EVLT | Intervention Type: PROCEDURE; Name: Surgery - Saphenofemoral ligation, saphenous strip and avulsions; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: EVLT; Assigned to Arm(s): EVLT
D: Arm Label: Conventional Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Surgery | Arm Label: Radiofrequency Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency Ablation | Intervention Type: PROCEDURE; Name: Conventional Surgery; Assigned to Arm(s): Conventional Surgery | Intervention Type: PROCEDURE; Name: Radiofrequency Ablation; Assigned to Arm(s): Radiofrequency Ablation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Moderate and Severe Mixed Urinary Incontinence in Female: a Multicenter, Noninferiority, Randomized Controlled Trial
Brief Summary: A noninferiority randomized controlled trial aimed at comparing the effect and safety of electroacupuncture versus the pelvic floor muscle training (PFMT) plus solifenacin for mixed urinary incontinence (MUI).


Options:
A: Arm Label: EA; Type: EXPERIMENTAL; Interventions: Other: electroacupncture | Arm Label: Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron 50 MG [Myrbetriq] | Intervention Type: OTHER; Name: electroacupncture; Assigned to Arm(s): EA | Intervention Type: DRUG; Name: Mirabegron 50 MG [Myrbetriq]; Assigned to Arm(s): Medication
B: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Sham acupuncture; Type: SHAM_COMPARATOR; Interventions: Other: Sham acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Sham acupuncture; Assigned to Arm(s): Sham acupuncture
C: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: Solifenacin plus PFMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: solifenacin, Procedure: PFMT | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin plus PFMT | Intervention Type: PROCEDURE; Name: PFMT; Assigned to Arm(s): Solifenacin plus PFMT
D: Arm Label: Electrical pudendal nerve stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Electrical pudendal nerve stimulation | Arm Label: PFM training with Transvaginal ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PFM training, Behavioral: Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Electrical pudendal nerve stimulation; Assigned to Arm(s): Electrical pudendal nerve stimulation | Intervention Type: BEHAVIORAL; Name: PFM training; Assigned to Arm(s): PFM training with Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Transvaginal ES; Assigned to Arm(s): PFM training with Transvaginal ES

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Moderate and Severe Mixed Urinary Incontinence in Female: a Multicenter, Noninferiority, Randomized Controlled Trial
Brief Summary: A noninferiority randomized controlled trial aimed at comparing the effect and safety of electroacupuncture versus the pelvic floor muscle training (PFMT) plus solifenacin for mixed urinary incontinence (MUI).


Options:
A: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4
C: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: Solifenacin plus PFMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: solifenacin, Procedure: PFMT | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin plus PFMT | Intervention Type: PROCEDURE; Name: PFMT; Assigned to Arm(s): Solifenacin plus PFMT
D: Arm Label: 1 Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: 2 Bladder Health Class; Type: EXPERIMENTAL; Interventions: Behavioral: Bladder Health class | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 1 Usual Care | Intervention Type: BEHAVIORAL; Name: Bladder Health class; Assigned to Arm(s): 2 Bladder Health Class

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians
Brief Summary: Musculoskeletal disorders and stress of employees remain a major problem in many occupations. The aim of this study is to investigate the effect of an individually tailored bio-psycho-social intervention strategy versus "usual care" ergonomics and standard physical exercises (reference group) on musculoskeletal pain, work disability, and stress in lab technicians with a history of work-related musculoskeletal pain.


Options:
A: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Active Workstation Intervention, Behavioral: Ergonomic Intervention, Behavioral: Email Intervention, Device: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application. | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ergonomic Intervention, Behavioral: Email Intervention, Device: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application. | Intervention Type: BEHAVIORAL; Name: Active Workstation Intervention; Assigned to Arm(s): Experimental Group | Intervention Type: BEHAVIORAL; Name: Ergonomic Intervention; Assigned to Arm(s): Active Control, Experimental Group | Intervention Type: BEHAVIORAL; Name: Email Intervention; Assigned to Arm(s): Active Control, Experimental Group | Intervention Type: DEVICE; Name: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.; Assigned to Arm(s): Active Control, Experimental Group
B: Arm Label: Biopsychosocial; Type: EXPERIMENTAL; Interventions: Behavioral: Biopsychosocial | Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reference | Intervention Type: BEHAVIORAL; Name: Biopsychosocial; Assigned to Arm(s): Biopsychosocial | Intervention Type: BEHAVIORAL; Name: Reference; Assigned to Arm(s): Reference
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: educational program, Other: exercise program, Other: Self-led exercises | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: educational program; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: exercise program; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-led exercises; Assigned to Arm(s): 1
D: Arm Label: Treadmill workstation; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill workstation, Behavioral: Health talk | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Behavioral: Health talk | Intervention Type: BEHAVIORAL; Name: Treadmill workstation; Assigned to Arm(s): Treadmill workstation | Intervention Type: BEHAVIORAL; Name: Health talk; Assigned to Arm(s): Control group, Treadmill workstation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Brief Summary: This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record.

The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: ACU-4429 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 10 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACU-4429; Assigned to Arm(s): ACU-4429 10 mg, ACU-4429 2.5 mg, ACU-4429 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Traditional and Participatory Dissemination of a Shared Decision Making Intervention
Brief Summary: Asthma is a common disease that affects people of all ages and has significant morbidity and mortality. Poor outcomes and health disparities related to asthma result in part from the difficulty of disseminating new evidence and paradigms of care delivery such as shared decision making (SDM) into clinical practice. This study will evaluate a novel mechanism for dissemination of an evidence-based SDM Toolkit for asthma care in primary care practices. The study is ideally suited to study dissemination methods because it will leverage a partnership between an established consortium of practice based research networks (PBRNs) and an advanced Medicaid Network.

This study will evaluate a novel dissemination process (FLOW) to spread an Asthma Shared Decision Making Toolkit to practices within a Medicaid network using a consortium of practice-based research networks (NCNC). The knowledge gained from this proposal and the partnerships formed between practice-based research networks and NC Medicaid will facilitate widespread dissemination to almost 300 practices.


Options:
A: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Arm Label: Facilitator-Led; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Traditional; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Asthma Shared Decision Making (SDM) Toolkit; Assigned to Arm(s): Facilitator-Led, Traditional
D: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial
Brief Summary: Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.


Options:
A: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
B: Intervention Type: DRUG; Name: triple co administration at once of the combination of Albendazole + ivermectin + azithromycin; Assigned to Arm(s): N/A
C: Arm Label: A; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: B; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: F; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: G; Type: EXPERIMENTAL; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Intervention Type: DRUG; Name: Mass treatment with oral azithromycin to an entire community; Assigned to Arm(s): A, B, C, F, G
D: Intervention Type: DRUG; Name: Mass treatment with oral azithromycin to an entire village; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial
Brief Summary: Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.


Options:
A: Arm Label: Azithomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithomycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
C: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
D: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B